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1. INTRODUCTION:
 Neurodegenerative disorders (like dementia, MS, PD, AD, stroke and
traumatic brain injury) cost directly to healthcare system over £134 billion
per annum in the UK and USA. These disorders affect the quality of life of
the patient.
 Brain matrix metalloproteinase-9 (MMP-9) levels increase in
neurodegenerative disorders. An enzyme that plays an important role in
many pathological processes of brain injuries and inflammation.
The Challenge
 Conventional drug delivery systems have number of limitations such as
route of administration (intracranial injection), bioavailability (permeability
across the BBB), and the safety of the carrier material.
Our approach
 We aim to develop a safe and smart material that forms a micellar drug
delivery system with the ability to target the brain specifically and release a
payload at the suitable region. Our approach is to apply state-of-the-art
integrated experimental and computational methods to identify the smart
enzyme responsive materials (Figure 1).
 The key advantages of our smart biomaterial are; permeability across the
BBB and being responsive to MMP-9.
2. METHODS:
 Experimental data was analysed by applying statistical models; Lamort,
Kridel , Kcat/KM and Ratnikov datasets in relation to MMP-9 cleavable
peptides.
 Molecular docking was applied to identify MMP-9 cleavable peptides with
desired sensitivity.
 Synthesis of suitable peptides using a CEM Liberty Blue synthesizer, and
characterization via Liquid chromatography–mass spectrometry (LC-MS).
 Conjugation of Cholesteryl chloroformate with peptide, using N,N-
Diisopropylethylamine (DIPEA) and Dimethylformamide (DMF).
 Characterizing the self-assembled nano-micelles using transmission
electron microscopy (TEM).
3. RESULTS:
 Y_scores were calculated as average of Lamort, Ratnikov and Kridel for
literature known sequences (Table 1).
 Y_score against log Kcat/KM values of known peptides gave a
polynomial regression curve with R2 = 0.9048 (Figure 2).
 The frequency distribution of amino acids in natural materials that are
responsive to MMP-9 is shown in Figure 3. This identifies key features of
known substrates.
 Figure 4 shows how a good substrate for MMP-9 is predicted to be
accommodated in the enzyme active site. This provides an explanation
for many of the preferences shown in Figure 3.
 Table 2 presents a list of novel MMP-9 cleavable peptides with predicted
Y_score and Kcat/KM. These are from a database of 1.2 million MMP-9
cleavable peptides that were generated by applying the above statistical
and molecular modelling techniques.
 TEM image of self-assembled nano-micelle with MMP-9 cleavable
peptide and a short rabies virus glycoprotein (sRVG) shuttle peptide
(Figure 5). The size of nano-micelles ranged from 50-200 nm.
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4. CONCLUSIONS:
 Novel MMP-9 cleavable peptides were generated by
applying computational methods.
 Self assembled nano-micelles were formulated with
MMP-9 cleavable and brain targeting peptides.
Table 1. A list of known MMP-9 substrates, processed using statistical techniques to assign cleavability scores. 
Figure 2. A plot of 
Y_score and log 
Kcat/KM values  
Figure 4. Characterising suitable biomaterial by docking using a structure of the enzyme taken from the 
protein databank. A peptide (PEGLW) after autodocking is shown in cyan;  it can be observed that 
“Leu” extends into the  S1’ pocket and “Trp” wraps around the bridge over the S1’ pocket.
Figure 1. Schematic presentation of the core of the smart biomaterial and 
mechanism of action of Smart-MMP-9 Responsive drug delivery system..  
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Sequence Probability Lamort Ratnikov Kridel Kcat/KM Y_Score
KAG-LLC 4.3636 0.47 -0.11 251 0.18
KG-LC 8.22765 0.47 358 0.47
SGRR-LLSRTA 0.51 3.61 0.50 0.12 1,200 1.41
RPLA-LWRSQ 4.12 4.03 0.69 0.49 2,000 1.74
RGLA-LWRSQ 0.36 3.37 0.56 0.47 2,000 1.47
GPLE-LEEAQ 29.73 4.06 0.55 0.45 2,000 1.69
EAAPSS-VIAATE 24.05 4.13 0.53 0.46 2,000 1.71
SGLRPAK-STA 23.23 3.74 0.64 0.00 5,800 1.46
PLG-LEEA 46.53 3.87 0.66 0.46 8,000 1.66
GPQG-IAGQ 1449.48 4.00 0.62 0.27 8,400 1.63
SGQPHY-LTTA 27.00 3.84 0.65 0.37 8,800 1.62
IPES-LRAG 38.64 4.07 0.66 0.36 12,600 1.70
SGFGSRY-LTA 52.20 3.76 0.63 0.11 13,200 1.50
GPLG-LERAQ 160.15 4.11 0.62 0.51 14,000 1.75
GAMF-LEAIP 6.26 4.06 0.60 0.26 15,000 1.64
RPLA-LEESQ 4.08 3.99 0.60 0.44 21,000 1.68
KPAG-LLGC 191.40 4.08 0.62 0.45 24,000 1.72
SGPLF-YSVTA 11.48 4.10 0.67 0.37 25,600 1.71
PLA-LWRSQ 5.64 4.03 0.68 0.49 51,000 1.73
SGPRA-VSTTA 74.98 4.17 0.65 0.35 61,000 1.72
RPLG-LEEA 34.02 3.86 0.66 0.46 62,000 1.66
RPLE-LWRSQ 1.59 4.02 0.63 0.45 67,000 1.70
SGKIPRT-LTA 52.94 4.16 0.68 0.20 67,500 1.68
RPLG-LGAAQ 237.75 4.23 0.74 0.38 133,000 1.78
RPLA-LWEEQ 9.19 3.96 0.71 0.39 143,000 1.69
GPLG-LREAQ 566.23 4.15 0.71 0.50 160,000 1.79
SGKIPRR-LTA 29.81 4.09 0.72 0.18 160,000 1.66
SGKGPRQ-ITA 170.54 4.15 0.65 0.23 188,000 1.68
RPLA-LWESQ 5.67 3.99 0.69 0.49 198,000 1.72
RPLG-LGGAQ 638.64 4.24 0.74 0.38 270,000 1.79
RPLA-LRRSQ 7.63 4.12 0.69 0.44 291,000 1.75
RPLG-LWGAQ 482.56 4.19 0.74 0.51 750,000 1.81 Sequence Y_score Kcat/KM
PFM-AG 2.59 1,462,495 
PFR-AG 2.51 1,264,381 
PFR-LG 2.04 405,685 
PKR-LG 2.03 389,159 
PFR-FG 2.00 345,901 
Table 2. Novel MMP-9 cleavable 
peptides with predicted cleavability 
(Kcat/KM)  
Figure 5. TEM image 
of MMP-9 nano-
micelle with 
targeting ligand
